A message from Dr. John Bell, Scientific Director and Stéphanie Michaud, President & CEO Cancer is a disease that knows no boundaries. It is a leading cause of death worldwide, responsible for 8.8 million deaths per year. The disease is one of the biggest health challenges facing Canadians: 2 in every 5 of us… Read more »
Tag: John Bell
Ottawa Scientists Cure Aggressive Breast Cancer in Mice with Combination Therapy
By: The Ottawa Citizen A new Ottawa research study shows that “triple negative” breast cancer — a particularly aggressive form of the disease — can be successfully treated in mice with a combination of immunotherapies that weaponize the immune system in different ways. The study was published Wednesday in Science Translational Medicine, a… Read more »
Dr. John Bell receives award for Outstanding Achievements in Cancer Research
The Canadian Cancer Research Alliance (CCRA) today announced that Dr. John Bell, BioCanRx’s Scientific Director, will receive the award for Outstanding Achievements in Cancer Research for his pioneering work and ground-breaking scientific discoveries, which have propelled the entire field of oncolytic virus therapy forward, and his commitment to enabling translational research. The award is… Read more »
Global News takes a look into the science of immunotherapy
Could immunotherapy – a novel method of treatment that harnesses your body’s own immune system to fight cancer – be the new front line for cancer treatment? Global News 16X9 is providing viewers with a look at immunotherapy – a concept that is being dubbed the fourth pillar for cancer treatment. This approach to… Read more »
World-first clinical trial for oncolytic virus immunotherapy featured by The National
Last night, CBC TV’s The National introduced its audience to a novel clinical trial currently underway in Canada. The trial has been partially enabled by support from BioCanRx to manufacture the engineered viruses being given to the study’s participants. The clinical trial is testing a new investigational therapy called oncolytic virus immunotherapy, which… Read more »
Health research champion Drew Lyall dies at 49
Media release Andrew Lyall (Drew), founding President and CEO of BioCanRx, died this weekend, after he, his family and physicians waged a long fight against melanoma. He was 49. Drew’s influence on health research, especially the biomedical world of stem cell research, was strong and unmistakable – extraordinary because he was not… Read more »
First cancer-killing virus therapy approved by the FDA
On Oct. 27, 2015, the U.S. FDA gave its first approval for the use of a cancer-killing virus therapy, or oncolytic virus. Specifically, the FDA approved Amgen’s Imlygic, which is generically known as T-VEC, for the treatment of melanoma lesions in the skin and lymph nodes. “This approval is a huge milestone for the… Read more »
BioCanRx investigators receive $5M to develop virus therapy for prostate cancer
News item Prostate Cancer Canada and the Movember Foundation have partnered to award $5 million to 2020 to a multi-disciplinary team of scientists and clinicians led by BioCanRx Scientific Director, Dr. John Bell. The team is mainly composed of BioCanRx network investigators who are working together to develop a treatment specifically for prostate cancer… Read more »
Dr. John Bell named Top 25 in Ottawa
News item Our Scientific Director, Dr. John Bell, was honoured by Ottawa Life Magazine as one of the Top 25 People in Ottawa. He was recognized for pioneering research on virus therapy as a form of cancer treatment and as a world-renowned scientist at the Ottawa Hospital Research Institute (OHRI). See Ottawa Life for… Read more »
Cancer patients treated in world-first clinical trial of Canadian viral therapy
Clinical Trials, Media release Canadian researchers have launched the world’s first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and… Read more »
